- Email: [email protected]
PROTECTIVE EFFECT OF APITHERAPY PRODUCTS AGAINST CARBON TETRACHLORIDE-INDUCED HEPATOTOXICITY IN WISTAR RATS
S6
Abstracts from 10th Congress of the European Federation of Internal Medicine/European Journal of Internal Medicine 22S (2011) S1–S112
Methods: We retrospectively analyzed the medical records of 903 patients who presented to the ED with symptoms of abdominal pain, over a 12 month period. Univariate and multivariable logistic regression analysis was used to study the effect of various factors in hospital admission. Results: Overall 239 (26%) patients were hospitalized during our study period. Hospitalized subjects were significantly older (55 vs. 40 years) and had a higher proportion of male patients (51.9% vs. 42.1%) (p<0.05). Furthermore hospitalized subjects had a higher proportion of leukocytosis (55.8% vs. 19.3%) and included a higher percentage of febrile patients (10.6% vs. 4.9%) (p<0.05). The multivariable logistic regression analysis showed that only leukocytosis was significantly associated with patients’ admission to the hospital (Exp(B)=0.16, p<0.05) Conclusions: Older and male patients with fever and elevated white blood cell count are more likely to have significant pathology requiring admission to the hospital for further evaluation.
were normal. Serology against of CMV showed Ig G negative with Ig M 95 UI/mL, monoclonal gammapathy (Ig G lambda 0,6 gr/dl). The rest of tests were normal: coproculture, flow cytometry of peripheral blood, HCV, HIV, EBV, Syphilis, ANA, lupus anticoagulant, anticardiolipin antibodies, Factor V Leiden mutation, protein C and S deficiency, Methyltetrahydrofolate reductase mutation, G20210A prothrombin mutation, JAK2V 616 and homocistein levels. Anticoagulant therapy was begun with acenocumarol. After 3 months, the antiphospolipid antibody remained negative, monoclonal gammapathy had disappeared and abdominal CT showed resolution of thrombosis while serological test showed an increased level of Ig G against CMV with mild persistent lymphocytosis. Conclusion: In patients with CMV infection and abdominal symptoms, mesenteric thrombosis should be ruled out, to initiate anticoagulant therapy as early as possible.
PROTECTIVE EFFECT OF APITHERAPY PRODUCTS AGAINST CARBON TETRACHLORIDE-INDUCED HEPATOTOXICITY IN WISTAR RATS
INFLUENCE OF INTERNATIONAL GUIDELINES (TASC II) ON THE MANAGEMENT OF CARDIOVASCULAR RISK FACTORS IN TYPE II DIABETIC PATIENTS WITH PERIPHERAL ARTERIAL DISEASE (PAD)
Ca Ûlin Vasile Andrit¸oiu1, Anca Irina Prisa Ûcaru2, Vasile Andrit¸oiu3, Ionel Marcel Popa1. 1Department of Physical Chemistry, Faculty of Chemical Engineering and Environmental Protection, “Gheorghe Asachi” Technical University, Iaüi, Romania; 2Department of Natural and Synthetic Polymers, Faculty of Chemical Engineering and Environmental Protection, “Gheorghe Asachi” Technical University, Iaüi, Romania; 3Department of Cellular and Molecular Biology, University of Medicine and Pharmacy ,,Gr. T. Popa”, Iaüi, Romania Background: Toxic hepatopathy represents a pathology with a continuously growing occurence. Carbon tetrachloride (CCl4) is a well-known substance used in producing experimental models of chemically induced hepatic injury. This study was designed to investigate the protective effects of the apitherapy products against CCl4 induced hepatotoxicity in Wistar rats. Methods: Hepatic lesion was induced by intraperitoneal injection of CCl4 (dissolved in paraffin oil, 10% solution). Two ml per 100 g were administered, once at 2 days, for 2 weeks. Hepatoprotective effect was achieved with apitherapy products purchased from Laboratory Stupina (Apiregya, ApiImunomod, ApiImunostim, ApiImunostim Forte). Results: Administration of apitherapy diet to laboratory animals with CCl4 induced hepatopathy determines, when compared to the group which was given CCl4 without protection, the following modifications regarding: I) enzymatic profile –decrease of hepatic enzymes: aspartate aminotransferase (385.1 ± 44.95 versus 93.7 ± 13.75), alanine aminotransferase (99.33 ± 21.51 versus 51.81 ± 13.72), alkaline phosphatase (170.4 ± 14.82 versus 110.9 ± 26.3), gamma-glutamyl transferase (0.95 ± 0.34 versus 0.55 ± 0.36); II) lipid profile – decrease of values for: total cholesterol (95.3 ± 11.83 versus 59.6±7.33), triglycerides (181.2±35.24 versus 84.5±18.42), very low density lipoproteins (36±7.03 versus 17±3.74), increase of high-density lipoproteins (36.64±3.4 versus 50.45±6.72); III) protein profile: increase of total proteins levels (5.273±0.53 versus 6.92±0.46), increase of albumin values (15.1±3.28 versus 40.12±3.39), decrease of globulin levels (84.5±3.24 versus 59.9 ± 3.37), increase of albumin/globulin ratio (0.17 ± 0.04 versus 0.67±0.08). Conclusion: Administration of apitherapy products has a significant positive effect on laboratory animals with chemically induced hepatopathy. PORTAL AND MESENTERIC VEIN THROMBOSIS SECONDARY TO CYTOMEGALOVIRUS HEPATITIS Anniccherico-Sánchez F.J., Alonso-Martínez J.L., Urbieta-Echezarreta M. Hospital Complex of Navarra.Dpt of Internal Medicine-A Pamplona. Navarra. Spain Background: Thrombosis is a rare complication of cytomegalovirus (CMV) infecton in immunocompetent patient. There are reports of 40 patients with CMV infection and thrombosis in differents localitations, 18 of them hepaticmesenteric-portal vein thrombosis. We communicate a new case of portal venous thrombosis associated with CMV infection, Case: A man of 66 years old, with history of surgery for hepatic Echinococcus granulosus cyst and surgical reparation of groin hernias in his youth, was admitted for persistent fever and abdominal pain located in epigastrium since one month before. His GP began antibiotic therapy with claritromicin and subsequently levofloxacin for suspected pneumony. No others treatment was taken. A CT of thorax and abdomen showed rests of fibrotics tracts in the liver and thrombosis spleno-portal. Esophagogastroduodeonoscopy and colonoscopy
Dafni Koumoutsea1,2, Konstantina Filioti1, Pantelis Kapralos1, Eleni Antoniadou1,6, Panagiota Thalassinou1, Damianos Aslanoglou2, Nikolaos Christodoulou3, Ioannis Griveas4, Ioannis Megas2, Vasilios Tsiligiris5, Dimitrios Patsios1. 1First Department of Internal Medicine, 401 General Military Hospital of Athens, Greece; 2Department of Endocrinology, 401 General Military Hospital of Athens, Greece; 3Department of Cardiology, 401 General Military Hospital of Athens, Greece; 4Department of Nephrology (Renal Medicine), 401 General Military Hospital of Athens, Greece; 5Department of Vascular Surgery, 401 General Military Hospital of Athens, Greece; 6Health Center of Spata, Athens, Greece Background/Aim: Recent data on the management of cardiovascular risk factors in high risk patients shows that dyslipidemia is still being treated in an inadequate way especially in type II diabetic patients. This study analyzes the influence of the recommendation of the Trans-Atlantic Inter-Society Consensus for the management of PAD (TASC II) on the actual daily practice. Materials - Methods: In this retrospective cohort study we analyzed totalcholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and fasting blood glucose using capillary blood in type II diabetic patients with PAD, who had been admitted to five (5) outpatient departments of the same hospital (internal medicine dept, endocrinology dept, cardiology dept, nephrology dept, vascular surgery dept) for the first time. Besides recording complete medical history and cardiovascular risk factors, an ABI (Ankle-Brachial Index) measurement and a carotid duplex ultrasonography were performed at presentation (on admission). We studied 69 type II diabetic patients with PAD (43 males/26 females) with a mean age (±SD) of 71,7±8,5 years, a mean BMI (±SD) of 28,6±4,8 kgr/m2 and a mean waist circumference (±SD) of 103,4±11,7 cm. The arterial blood pressure levels were within acceptable limits ( 130/80 mmHg) under antihypertensive treatment in 64 patients (92,75%). Metabolic syndrome according to the NCEP-ATP III criteria (2001) was present in 58 patients (84,05%). Results: 29 patients (42,02%) had clinically manifested and objectively documented vascular lesions. Total-cholesterol was 186±42 mgr/dl, LDL-chol: 96±34 mgr/dl, HDL-chol: 44±14 mgr/dl and triglycerides 222±108 mgr/dl. A total of only 34,78% (24 patients) in this high risk cohort attained the LDL-chol target levels according to the TASC II guidelines. A total of 68,11% (47 patients) were on HMG-CoA-reductase inhibitors (statins) and a total of 59,42% (41 patients) were on platelet aggregation inhibitors. Conclusions: According to our results we found poor adherence to international guidelines for secondary prevention in type II diabetic patients with PAD in the above five (5) outpatient departments. PERITONEAL TUBERCULOSIS: CASE REPORT Ana Antunes, André Carneiro, André Santa Cruz, Juliana Martins, Guilherme Gomes. Department of Internal Medicine, Hospital de Braga, Braga Portugal Background: Peritoneal tuberculosis mainly affects patients with risk factors, usually by reactivation of latent infection. Insidious onset and nonspecific clinical presentation retard diagnosis by a mean of 4 months. The most common presentation is abdominal pain, fever and ascites. The gold standard
Abstracts from 10th Congress of the European Federation of Internal Medicine/European Journal of Internal Medicine 22S (2011) S1–S112
Methods: We retrospectively analyzed the medical records of 903 patients who presented to the ED with symptoms of abdominal pain, over a 12 month period. Univariate and multivariable logistic regression analysis was used to study the effect of various factors in hospital admission. Results: Overall 239 (26%) patients were hospitalized during our study period. Hospitalized subjects were significantly older (55 vs. 40 years) and had a higher proportion of male patients (51.9% vs. 42.1%) (p<0.05). Furthermore hospitalized subjects had a higher proportion of leukocytosis (55.8% vs. 19.3%) and included a higher percentage of febrile patients (10.6% vs. 4.9%) (p<0.05). The multivariable logistic regression analysis showed that only leukocytosis was significantly associated with patients’ admission to the hospital (Exp(B)=0.16, p<0.05) Conclusions: Older and male patients with fever and elevated white blood cell count are more likely to have significant pathology requiring admission to the hospital for further evaluation.
were normal. Serology against of CMV showed Ig G negative with Ig M 95 UI/mL, monoclonal gammapathy (Ig G lambda 0,6 gr/dl). The rest of tests were normal: coproculture, flow cytometry of peripheral blood, HCV, HIV, EBV, Syphilis, ANA, lupus anticoagulant, anticardiolipin antibodies, Factor V Leiden mutation, protein C and S deficiency, Methyltetrahydrofolate reductase mutation, G20210A prothrombin mutation, JAK2V 616 and homocistein levels. Anticoagulant therapy was begun with acenocumarol. After 3 months, the antiphospolipid antibody remained negative, monoclonal gammapathy had disappeared and abdominal CT showed resolution of thrombosis while serological test showed an increased level of Ig G against CMV with mild persistent lymphocytosis. Conclusion: In patients with CMV infection and abdominal symptoms, mesenteric thrombosis should be ruled out, to initiate anticoagulant therapy as early as possible.
PROTECTIVE EFFECT OF APITHERAPY PRODUCTS AGAINST CARBON TETRACHLORIDE-INDUCED HEPATOTOXICITY IN WISTAR RATS
INFLUENCE OF INTERNATIONAL GUIDELINES (TASC II) ON THE MANAGEMENT OF CARDIOVASCULAR RISK FACTORS IN TYPE II DIABETIC PATIENTS WITH PERIPHERAL ARTERIAL DISEASE (PAD)
Ca Ûlin Vasile Andrit¸oiu1, Anca Irina Prisa Ûcaru2, Vasile Andrit¸oiu3, Ionel Marcel Popa1. 1Department of Physical Chemistry, Faculty of Chemical Engineering and Environmental Protection, “Gheorghe Asachi” Technical University, Iaüi, Romania; 2Department of Natural and Synthetic Polymers, Faculty of Chemical Engineering and Environmental Protection, “Gheorghe Asachi” Technical University, Iaüi, Romania; 3Department of Cellular and Molecular Biology, University of Medicine and Pharmacy ,,Gr. T. Popa”, Iaüi, Romania Background: Toxic hepatopathy represents a pathology with a continuously growing occurence. Carbon tetrachloride (CCl4) is a well-known substance used in producing experimental models of chemically induced hepatic injury. This study was designed to investigate the protective effects of the apitherapy products against CCl4 induced hepatotoxicity in Wistar rats. Methods: Hepatic lesion was induced by intraperitoneal injection of CCl4 (dissolved in paraffin oil, 10% solution). Two ml per 100 g were administered, once at 2 days, for 2 weeks. Hepatoprotective effect was achieved with apitherapy products purchased from Laboratory Stupina (Apiregya, ApiImunomod, ApiImunostim, ApiImunostim Forte). Results: Administration of apitherapy diet to laboratory animals with CCl4 induced hepatopathy determines, when compared to the group which was given CCl4 without protection, the following modifications regarding: I) enzymatic profile –decrease of hepatic enzymes: aspartate aminotransferase (385.1 ± 44.95 versus 93.7 ± 13.75), alanine aminotransferase (99.33 ± 21.51 versus 51.81 ± 13.72), alkaline phosphatase (170.4 ± 14.82 versus 110.9 ± 26.3), gamma-glutamyl transferase (0.95 ± 0.34 versus 0.55 ± 0.36); II) lipid profile – decrease of values for: total cholesterol (95.3 ± 11.83 versus 59.6±7.33), triglycerides (181.2±35.24 versus 84.5±18.42), very low density lipoproteins (36±7.03 versus 17±3.74), increase of high-density lipoproteins (36.64±3.4 versus 50.45±6.72); III) protein profile: increase of total proteins levels (5.273±0.53 versus 6.92±0.46), increase of albumin values (15.1±3.28 versus 40.12±3.39), decrease of globulin levels (84.5±3.24 versus 59.9 ± 3.37), increase of albumin/globulin ratio (0.17 ± 0.04 versus 0.67±0.08). Conclusion: Administration of apitherapy products has a significant positive effect on laboratory animals with chemically induced hepatopathy. PORTAL AND MESENTERIC VEIN THROMBOSIS SECONDARY TO CYTOMEGALOVIRUS HEPATITIS Anniccherico-Sánchez F.J., Alonso-Martínez J.L., Urbieta-Echezarreta M. Hospital Complex of Navarra.Dpt of Internal Medicine-A Pamplona. Navarra. Spain Background: Thrombosis is a rare complication of cytomegalovirus (CMV) infecton in immunocompetent patient. There are reports of 40 patients with CMV infection and thrombosis in differents localitations, 18 of them hepaticmesenteric-portal vein thrombosis. We communicate a new case of portal venous thrombosis associated with CMV infection, Case: A man of 66 years old, with history of surgery for hepatic Echinococcus granulosus cyst and surgical reparation of groin hernias in his youth, was admitted for persistent fever and abdominal pain located in epigastrium since one month before. His GP began antibiotic therapy with claritromicin and subsequently levofloxacin for suspected pneumony. No others treatment was taken. A CT of thorax and abdomen showed rests of fibrotics tracts in the liver and thrombosis spleno-portal. Esophagogastroduodeonoscopy and colonoscopy
Dafni Koumoutsea1,2, Konstantina Filioti1, Pantelis Kapralos1, Eleni Antoniadou1,6, Panagiota Thalassinou1, Damianos Aslanoglou2, Nikolaos Christodoulou3, Ioannis Griveas4, Ioannis Megas2, Vasilios Tsiligiris5, Dimitrios Patsios1. 1First Department of Internal Medicine, 401 General Military Hospital of Athens, Greece; 2Department of Endocrinology, 401 General Military Hospital of Athens, Greece; 3Department of Cardiology, 401 General Military Hospital of Athens, Greece; 4Department of Nephrology (Renal Medicine), 401 General Military Hospital of Athens, Greece; 5Department of Vascular Surgery, 401 General Military Hospital of Athens, Greece; 6Health Center of Spata, Athens, Greece Background/Aim: Recent data on the management of cardiovascular risk factors in high risk patients shows that dyslipidemia is still being treated in an inadequate way especially in type II diabetic patients. This study analyzes the influence of the recommendation of the Trans-Atlantic Inter-Society Consensus for the management of PAD (TASC II) on the actual daily practice. Materials - Methods: In this retrospective cohort study we analyzed totalcholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides and fasting blood glucose using capillary blood in type II diabetic patients with PAD, who had been admitted to five (5) outpatient departments of the same hospital (internal medicine dept, endocrinology dept, cardiology dept, nephrology dept, vascular surgery dept) for the first time. Besides recording complete medical history and cardiovascular risk factors, an ABI (Ankle-Brachial Index) measurement and a carotid duplex ultrasonography were performed at presentation (on admission). We studied 69 type II diabetic patients with PAD (43 males/26 females) with a mean age (±SD) of 71,7±8,5 years, a mean BMI (±SD) of 28,6±4,8 kgr/m2 and a mean waist circumference (±SD) of 103,4±11,7 cm. The arterial blood pressure levels were within acceptable limits ( 130/80 mmHg) under antihypertensive treatment in 64 patients (92,75%). Metabolic syndrome according to the NCEP-ATP III criteria (2001) was present in 58 patients (84,05%). Results: 29 patients (42,02%) had clinically manifested and objectively documented vascular lesions. Total-cholesterol was 186±42 mgr/dl, LDL-chol: 96±34 mgr/dl, HDL-chol: 44±14 mgr/dl and triglycerides 222±108 mgr/dl. A total of only 34,78% (24 patients) in this high risk cohort attained the LDL-chol target levels according to the TASC II guidelines. A total of 68,11% (47 patients) were on HMG-CoA-reductase inhibitors (statins) and a total of 59,42% (41 patients) were on platelet aggregation inhibitors. Conclusions: According to our results we found poor adherence to international guidelines for secondary prevention in type II diabetic patients with PAD in the above five (5) outpatient departments. PERITONEAL TUBERCULOSIS: CASE REPORT Ana Antunes, André Carneiro, André Santa Cruz, Juliana Martins, Guilherme Gomes. Department of Internal Medicine, Hospital de Braga, Braga Portugal Background: Peritoneal tuberculosis mainly affects patients with risk factors, usually by reactivation of latent infection. Insidious onset and nonspecific clinical presentation retard diagnosis by a mean of 4 months. The most common presentation is abdominal pain, fever and ascites. The gold standard